Skip to main navigation

English
Français

IR Navigation

Overview
News
Events & Presentations
- Events
- Presentations
Stock Information
Financials
Governance
Resources

Press Releases

Press Releases

Year

23 Sep 2024

GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval

19 Sep 2024

GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update

26 Jul 2024

GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis

09 Jul 2024

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

17 Jun 2024

GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH

10 Jun 2024

GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis

29 May 2024

GENFIT to Present Latest ACLF Research at EASL Congress™ 2024

22 May 2024

GENFIT: May 22, 2024 Combined Shareholders Meeting Results

14 May 2024

GENFIT Reports First Quarter 2024 Financial Information

25 Apr 2024

GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)

15 Apr 2024

GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents

05 Apr 2024

GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F

04 Apr 2024

GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update

29 Feb 2024

GENFIT Announces Revenues and Cash Position as of December 31, 2023

15 Jan 2024

GENFIT Announces 2024 Financial Calendar

11 Jan 2024

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Shareholder Tools

Print Page
Email Alerts
RSS
Contact IR

Request E-mail Alerts

GENFIT Headquarters
Parc Eurasanté 885, Avenue Eugène Avinée 59120 Loos France GENFIT Corp
45 Propect St. Suite 214, Cambridge, MA02139, USA

All rights reserved.